Table 3.
Journals | Paper number | Top-paper number | TPR* | Total citations | ACI | Citation per paper per year | IF (2023) |
---|---|---|---|---|---|---|---|
Nature | 51 | 16 | 31.4% | 52,194 | 1023.4 | 75.7 | 64.8 |
Cell | 37 | 11 | 29.7% | 28,103 | 759.5 | 64.6 | 64.5 |
Nature reviews cancer | 27 | 8 | 29.6% | 18,463 | 683.8 | 56.9 | 78.5 |
Cancer cell | 53 | 8 | 15.1% | 24,082 | 454.4 | 41.5 | 50.3 |
Cell stem cell | 72 | 8 | 11.1% | 28,703 | 398.7 | 38.9 | 23.9 |
PNAS | 91 | 8 | 8.8% | 37,422 | 411.2 | 29.8 | 11.1 |
Oncogene | 73 | 2 | 2.7% | 18,963 | 259.8 | 25.4 | 8.0 |
Molecular cancer | 37 | 1 | 2.7% | 7267 | 196.4 | 24.5 | 37.3 |
Oncotarget | 51 | 1 | 2% | 9211 | 180.6 | 22.5 | N |
Cancer research | 184 | 13 | 7.1% | 55,003 | 298.9 | 22.1 | 11.2 |
Percentage of top-papers among all papers with more than 100 citations in CSCs in a journal.